Compassionate use of cefiderocol in a complex case of extensively drug-resistant Acinetobacter baumannii fracture-related infection: a comprehensive approach and multidisciplinary management
Preprint
- 20 March 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose Fracture-related infections (FRI) pose a difficult management problem, as they require numerous surgical interventions and extended antibiotic treatments, especially when a multidrug-resistant organism is involved, with a paucity of available literature that provides guidance. Results A 42-year-old male presents an open diaphyseal tibia and fibula fracture, complicated by soft tissue necrosis and infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-Ab). Initially treated with a damage control external fixator, the patient underwent multiple surgical procedures, including radical debridement, negative pressure wound therapy, external fixator revisions and reconstructive surgery using a latissimus dorsi free flap. The emergence of colistin resistance in the Acinetobacter baumannii strain led to the compassionate use of cefiderocol, finally achieving clinical cure. Conclusions This case report is one of the firsts that highlights the potential efficacy of cefiderocol in treating challenging bone and joint infections sustained by XDR-Ab. The successful outcome also emphasizes the importance of a comprehensive, multidisciplinary approach in achieving favorable results in complex FRI.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)International Journal of Antimicrobial Agents, 2022
- Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infectionJAC-Antimicrobial Resistance, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumanniiJournal of Global Antimicrobial Resistance, 2020
- General treatment principles for fracture-related infection: recommendations from an international expert groupArchives of orthopaedic and trauma surgery, 2019
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative BacilliDrugs, 2019
- Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosaJournal of Microbiology, 2018
- Uncovering the mechanisms of Acinetobacter baumannii virulenceNature Reviews Microbiology, 2017
- Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacerInternational Journal of Antimicrobial Agents, 2014
- Management of a Multidrug-Resistant Pseudomonas Aeruginosa Infected Total Knee Arthroplasty Using Colistin. A Case Report and Review of the LiteratureThe Journal of Arthroplasty, 2007